Aptevo regains Nasdaq compliance following $15.9 million equity raise

Aptevo Therapeutics Inc . (NASDAQ:APVO) announced Tuesday that it has regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2.5 million in stockholders’ equity.

The company received confirmation from the Nasdaq Listing Qualifications Staff after previously disclosing that it was not in compliance for the quarter ended March 31, 2025. According to a statement based on the company’s SEC filing, Aptevo demonstrated compliance by raising approximately $15.9 million in gross proceeds through additional equity capital during the quarter ended June 30, 2025.

As a result, Aptevo reported that it now believes it has stockholders’ equity of at least $2.5 million, meeting the continued listing requirements for The Nasdaq Stock Market LLC.

The information in this article is based on a press release statement included in Aptevo’s Form 8-K filing with the Securities and Exchange Commission.

In other recent news, Aptevo Therapeutics Inc. has successfully closed an $8 million registered direct offering. The biotechnology company sold 2,465,000 shares of common stock or pre-funded warrants, along with warrants to purchase up to 12,325,000 additional shares. Roth Capital Partners (WA:CPAP) served as the placement agent for this transaction. Aptevo plans to use the net proceeds to further its clinical development programs and for general corporate purposes. Additionally, Aptevo has expanded its immuno-oncology pipeline by introducing APVO455, a preclinical bispecific T-cell engager targeting solid tumors. This new therapy joins mipletamig, which has shown an 85% remission rate in frontline acute myeloid leukemia (AML) patients in combination with standard treatments. The company reports that no cytokine release syndrome was observed in the initial cohorts of the ongoing RAINIER trial. Aptevo’s mipletamig has received orphan drug designation for AML, highlighting its potential in treating this aggressive blood cancer.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.